The use of primary cells in vitro is compromised by the limited quantity of cells that can be isolated from one donor, a lack of or very restricted proliferation capacity (e.g. hepatocytes) and/or the change from a quiescent to an activated state (e.g. hepatic stellate cells). The use of immortalized cell lines on the other hand, is compromised by their transformed, cancerous phenotype.
Using the upcyte® technology, primary cells are driven into proliferation using a viral gene transfer system, thus allowing controlled and reversible bypass of cell cycle control mechanisms without inducing immortalization, uncontrolled cell growth or changing the typical phenotype.
Therefore, upcyte® cells are available in sufficient quantities with a consistent quality that can be used for research, screening and drug development. We can expand up to 2000+ vials per cell type and donor – data from different studies can now be compared while working with the same donor. upcyte® cells have a distinct advantage over commonly used cells with respect to the virtually unlimited availability of differentiated cells.